Sec Form 4 Filing - GOLDENBERG CYNTHIA L @ IMMUNOMEDICS INC - 2015-06-10

Insider filing report for Changes in Beneficial Ownership
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: November 30, 2011
Estimated average burden hours per response... 0.5
1. Name and Address of Reporting Person
GOLDENBERG CYNTHIA L
2. Issuer Name and Ticker or Trading Symbol
IMMUNOMEDICS INC [ IMMU]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X __ Director _____ 10% Owner
X __ Officer (give title below) _____ Other (specify below)
President and CEO
(Last) (First) (Middle)
C/O IMMUNOMEDICS, INC., 300 AMERICAN ROAD
3. Date of Earliest Transaction (MM/DD/YY)
06/10/2015
(Street)
MORRIS PLAINS, NJ07950
4. If Amendment, Date Original Filed (MM/DD/YY)
6. Individual or Joint/Group Filing (Check Applicable Line)
__ X __ Form filed by One Reporting Person
_____ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/10/2015 M 15,300 A $ 2.67 524,857 ( 1 ) D
Common Stock 06/10/2015 S 15,300 D $ 4.6751 ( 2 ) ( 3 ) 509,557 ( 1 ) D
Common Stock 06/10/2015 M 15,120 A $ 2.67 5,296,537 I See footnote ( 4 )
Common Stock 06/10/2015 S 15,120 D $ 4.6745 ( 2 ) ( 5 ) 5,281,417 I See footnote ( 4 )
Common Stock 06/11/2015 M 84,700 A $ 2.67 594,257 ( 1 ) D
Common Stock 06/11/2015 S 84,700 D $ 4.3035 ( 3 ) ( 6 ) 509,557 ( 1 ) D
Common Stock 06/11/2015 M 21,191 A $ 1.75 530,748 ( 1 ) D
Common Stock 06/11/2015 S 21,191 D $ 4.3035 ( 3 ) ( 6 ) 509,557 ( 1 ) D
Common Stock 06/11/2015 M 93,989 A $ 2.67 5,375,406 I See footnote ( 4 )
Common Stock 06/11/2015 S 93,989 D $ 4.3046 ( 5 ) ( 6 ) 5,281,417 I See footnote ( 4 )
Common Stock 06/12/2015 M 58,512 A $ 1.75 568,069 ( 1 ) D
Common Stock 06/12/2015 S 58,512 D $ 4.2672 ( 3 ) ( 7 ) 509,557 ( 1 ) D
Common Stock 06/12/2015 M 70,841 A $ 2.67 5,352,258 I See footnote ( 4 )
Common Stock 06/12/2015 S 70,841 D $ 4.2668 ( 5 ) ( 7 ) 5,281,417 I See footnote ( 4 )
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(MM/DD/YY)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $ 2.67 06/10/2015 M 15,300 ( 8 ) 07/18/2015 Common Stock, par value $0.01 per share 15,300 $ 0 84,700 D
Stock Option (right to buy) $ 2.67 06/10/2015 M 15,120 ( 8 ) 07/18/2015 Common Stock, par value $0.01 per share 15,120 $ 0 284,880 I See footnote ( 9 )
Stock Option (right to buy) $ 2.67 06/11/2015 M 84,700 ( 8 ) 07/18/2015 Common Stock, par value $0.01 per share 84,700 $ 0 0 D
Stock Option (right to buy) $ 1.75 06/11/2015 M 2 1,191 ( 10 ) 06/15/2015 Common Stock, par value $0.01 per share 21,191 $ 0 128,809 D
Stock Option (right to buy) $ 2.67 06/11/2015 M 93,989 ( 8 ) 07/18/2015 Common Stock, par value $0.01 per share 93,989 $ 0 190,891 I See footnote ( 9 )
Stock Option (right to buy) $ 1.75 06/12/2015 M 58,512 ( 10 ) 06/15/2015 Common Stock, par value $0.01 per share 58,512 $ 0 70,297 D
Stock Option (right to buy) $ 2.67 06/12/2015 M 70,841 ( 8 ) 07/18/2015 Common Stock, par value $0.01 per share 70,841 $ 0 120,050 I See footnote ( 9 )
Reporting Owners
Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
GOLDENBERG CYNTHIA L
C/O IMMUNOMEDICS, INC.
300 AMERICAN ROAD
MORRIS PLAINS, NJ07950
X President and CEO
Signatures
/s/ Cynthia L. Goldenberg 06/12/2015
Signature of Reporting Person Date
Explanation of Responses:
( 1 )Includes a total of 190,000 shares held as joint tenants by the reporting person and her spouse, David M. Goldenberg, the Issuer's Chief Scientific Officer, Chief Medical Officer and Chairman of the Board of Directors.
( 2 )The price in column 4 is a weighted average price. The prices actually received in this transaction range from $4.65 to $4.71.
( 3 )The reporting person has provided to the issuer, and the issuer will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range reported.
( 4 )Such shares are held by the reporting person's spouse, by various trusts established for the benefit of the reporting person and/or family members of the reporting person, or by a majority-owned subsidiary of the Issuer, of which the reporting person is an officer. The reporting person disclaims beneficial ownership of these shares except to the extent of her pecuniary interests therein.
( 5 )The reporting person's spouse has provided to the issuer, and the issuer will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range reported.
( 6 )The price in column 4 is a weighted average price. The prices actually received in this transaction range from $4.21 to 4.61.
( 7 )The price in column 4 is a weighted average price. The prices actually received in this transaction range from $4.21 to 4.34.
( 8 )These stock options were granted pursuant to the Issuer's 2006 Stock Incentive Plan, and vested 25% on the first anniversary of the date of grant and 6.25% on a quarterly basis thereafter.
( 9 )The reporting person's spouse was granted these stock options pursuant to the Issuer's 2006 Stock Incentive Plan.
( 10 )These stock options were granted pursuant to the Issuer's 2006 Stock Incentive Plan, and vested immediately.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.